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Abstract The sensitivity of a K39 ELISA (Leishmania IgG,
Virion/Serion) for the detection of antibodies in patients with
imported leishmaniasis was compared with an immunofluo-
rescence assay (IFA), which was applied as Bgolden
standard^. The retrospective study comprised 93 IFA-
positive or borderline sera from 42 patients with visceral
(n=16) or cutaneous (n=26) leishmaniasis. Patients had ac-
quired infection predominately in the Mediterranean area or
the Middle East. The Leishmania species (Leishmania
donovani/infantum, Leishmania tropica, Leishmania major)
were identified by real-time PCR. The majority (94 %) of first
samples from patients with visceral leishmaniasis (VL) tested
positive by K39 ELISA. Antibody levels ranged from low to
very high (33.19–1990.00 U/ml; median 596.66 U/ml) but did
not correlate with the respective IFA titers. High K39 ELISA
values correlated with acute infection in immunocompetent
individuals. K39 antibodies declined in all individuals after
clinically successful therapy, but time to seronegativity varied
considerably (51 weeks to >6 years). In patients with cutane-
ous leishmaniasis (CL), the sensitivity of the K39 ELISAwas
low (23 %) compared to IFA (92 % positive). Antibody levels
ranged from low to medium (10.85–524.77 U/ml; median
19.77 U/ml). The highest antibody concentrations were seen
in L. infantum-infected individuals. Summarizing, a high K39
ELISAvalue indicates active VL. The assay is, like IFA, not a
measure for effective therapy but may support post-treatment
monitoring. Low level positivity can indicate subclinical, pre-
vious or clinically cured VL or even CL. The K39 ELISA can
supplement highly sensitive screening tests in the diagnosis
and follow-up of imported leishmaniasis.
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Introduction
Leishmaniasis is an infectious disease, caused by protozoic
parasites of the genus Leishmania. The disease occurs pre-
dominantly in tropical and subtropical climate zones.
Depending on the infecting species and the hosts’ immune
reaction, Leishmania can induce different clinical manifestations,
which are referred to as cutaneous leishmaniasis (CL), mucocu-
taneous leishmaniasis (MCL) or visceral leishmaniasis (VL).
Cutaneous leishmaniasis of the Old World is frequently caused
by Leishmania tropica, Leishmania major or Leishmania
aethiopica and is known as a self-limiting disease. Infections
with Leishmania donovani, Leishmania chagasi and—in
Europe—Leishmania infantum may also induce CL but tend to
induce visceral disease (VL; also known as kala-azar).
It is estimated that the annual worldwide incidence is approx-
imately 0.2 to 0.4 million cases of visceral and 0.7 to 1.2 million
cases of cutaneous leishmaniasis (Alvar et al. 2012). In north
European countries, where leishmaniasis is regarded as an
emerging disease, it is still rare and predominately imported
(Harms et al. 2003; Malik et al. 2006). In Germany, 16 cases of
VL and 23 cases of CL were recorded in the period between
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2001 and 2004, the majority of which originate from
Mediterranean holiday destinations (Weitzel et al. 2005).
Due to the non-specific symptoms of CL andVL, diagnosis is
often delayed in non-endemic countries (Gradoni 2013).
Diagnosis is based on direct pathogen detection methods, such
asmicroscopy, in vitro culturing ormolecular biological methods
like PCR. Also, the detection of specific antibodies by various
serological methods is common for MCL and VL, but is less
recommended for CL because of rather low sensitivity.
For cutaneous leishmaniasis, the diagnostic value of serol-
ogy depends on the causative Leishmania species, which dif-
fer in eliciting immune response (Romero et al. 2005) but also
on the immune response of the host and the sensitivity of the
assay used. Usually, antibody detection is most reliable in
immunocompetent individuals with VL and is used as a fast,
low invasive and efficient diagnostic method. In recent years,
assays based on a defined antigen, the kinesin-like protein
K39 derived from L. chagasi, are increasingly applied in en-
demic countries for the detection of patients with visceral dis-
ease. The assays are described as highly specific and sensitive
(Maalej et al. 2003; Chappuis et al. 2007; Maia et al. 2012)
and should indicate successful therapy.
Due to the limited number of imported cases, K39-based
assays are rarely applied in non-endemic countries. In this
study a K39-antigen based ELISA (SERION ELISA classic
Leishmania IgG) was tested for its suitability to detect anti-
bodies in cases with leishmaniasis imported into Germany for
the first time. The retrospective study, which included 42 pa-
tients with confirmed visceral or cutaneous infection, and an-
tibody response confirmed by IFA, should reveal to which
extent the serological results provide information on the kind
of clinical manifestation, the severity of the disease, and suc-
cessful treatment.
Material and methods
For the present study, 93 serum samples from 42 patients with
clinical and laboratory diagnosis of visceral leishmaniasis (n=
16) or cutaneous leishmaniasis (n=26) were selected from
archived material. The selection criteria were clinical symp-
toms for—or history of exposure to Leishmania spp., identi-
fication of the parasite in a clinical sample or follow-up after
specific therapy and seropositivity by IFA. The serum sam-
ples, collected at different clinical sites in the context of the
routine examination of returnees or immigrants from endemic
areas, were sent to the Institute for Microbiology,
Immunology and Parasitology for Leishmania serology. The
collection period was from 2006–2014.
The mean age of patients with VLwas 47 years (range 1.5–
80 years), the mean age of patients with CL was 44 years
(range 2–84 years). The male:female ratio was 12:4 (VL)
and 17:9 (CL), respectively.
For 37 patients, a first sample was available before initiation
of treatment (11 patients with VL, 26 patients with CL). From
four VL patients, the first sample was taken after the onset of
treatment. After treatment follow-up samples were available
from nine VL patients (min. 13 weeks, max. 145 weeks) and
six CL patients (min. 13 weeks, max. 106 weeks).
Serology: All serum samples had been tested individually
at the time of collection by an indirect fluorescence assay
(IFA) and were subsequently stored at−25 °C. Samples were
thawed to perform the K39 ELISA and for repeated IFA test-
ing in case of discrepant or unclear results to ensure continued
seroreactivity and stability.
IFA: The in-house assay was carried out using amastigotes
from a Mediterranean L. infantum isolate (strain B).
Cryosections with amastigotes were prepared with liver or
spleen taken from previously infected golden hamsters. The
IFA was performed using standard procedures. Serum dilution
(twofold) started at 1:10. For staining, a FITC-labelled anti-hu-
man Ig-conjugate (BioMérieux, France) was used at a dilution
of 1:100. Titers of 1:10 were considered as borderline, >1:10 as
positive for people without travel history to a country endemic
for Chagas. The IFA, which is highly sensitive for the detection
of OldWorld Leishmaniasis, served as Bgolden standard^. High
titers are commonly associated with visceral infection, moderate
or low titers with asymptomatic or cutaneous infection.
K39 ELISA: For ELISA analysis, the commercially avail-
able SERION ELISA classic Leishmania IgG (Virion\Serion
GmbH, Würzburg, Germany) was used in accordance to the
manufacturer’s instructions. The assay is based on a prepara-
tion of K39 and allows for quantitative data interpretation.
Antibody activities of 10–15 U/ml are evaluated as borderline,
values>15 U/ml are considered positive. Samples with a bor-
derline or positive result were confirmed by repeated testing.
Real-time PCR
Subgenus or species-specific primers and four TaqMan hy-
bridization probes were designed to detect and differentiate
L. major, L. donovani/infantum, L. braziliensis and
Leishmania tropica from one another in patient material based
on the glucose-6-phosphate sequences of these species
(Table 1). Two forward primers and a single reverse primer
amplify a region with differences that can be detected with
four TaqMan probes. In a total volume of 20 μl, 5 μl of
DNA was amplified using the Quantitect Multiplex NoRox
Kit (Qiagen, Hilden, Germany) in accordance to the manufac-
turer’s protocol with 200 nM of each forward and reverse
primer and 50 nM of each hybridization probe. Samples were
amplified and fluorescence acquired using a Rotorgene Q 5-
plex real-time machine (Qiagen). The following protocol was
used: 95 °C 15 min, 55 cycles of 94 °C 10 s, and 62 °C 30 s.
Fluorescence was acquired at the end of the binding/extension
step. Plasmids (1×105 copies/μl) containing each species-
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specific sequence were used as positive controls for the PCR.
To control for DNA extraction, L. donovani cultivated at
25 °C in supplemented L-15 Leibovitz Medium (Biochrom,
Berlin, Germany) was extracted in parallel with the patient
samples using the QIAamp DNA Mini Kit in a QIACube.
The identities of all strains had been verified by zymodeme
analysis and RFLP-PCR (Schoenian et al. 2001).
Serum and plasmawere eluted in 50–75μl of elution buffer
while whole blood was eluted in 100 μl of elution buffer.
Extraction of biopsies was performed using the QIAamp
DNA Mini Kit including a prior step of digestion with pro-
teinase K. Samples were used immediately for real-time PCR
or frozen until use at−20 °C.
DNA: As a control for inhibitors in the DNA extracted from
patient blood, a second reaction combining sample DNAwith
a plasmid containing a fragment of Mus musculus interferon-
gamma (mIFN-γ; GenBank: EF423643.1) was performed in
parallel (Albers et al. 2012). In short, in a total volume of 20 μl,
5 μl of sample DNA and 2 μl of mIFN-γ plasmid (1×106
copies/μl) were amplified using the Quantitect Multiplex
NoRox Kit (Qiagen) in accordance to the manufacturer’s pro-
tocol with 200 nM of forward and reverse primers and 50 nM
of the hybridization probe (Table 1). Cycling conditions were
the same as for the Leishmania spp. PCR. Samples were con-
sidered inhibited if Ct of the mIFN-γ plasmid was detected
≥3 cycles later than the Ct for the water control. By this meth-
od, the DNA from this patient cohort did not contain inhibitors
that needed to be controlled for by dilution or other means.
Results
IFA titers of all samples retested during the study were in con-
cordance with values achieved at the time of primary testing.
Visceral leishmaniasis: All but one of the first samples from
15 patients with VL tested positive by K39 ELISA. The ma-
jority of the patients was immunocompetent and got infected
in the Mediterranean area with L. infantum (Table 2). For a
few patients, travel history or the clinical symptoms were not
reported or the Leishmania species remained unknown (sam-
ples for PCR not available).
Regarding the immunocompetent VL patients with a first
sample before treatment (n=9) all IFA titers were high (2560–
20,000, median 10,000), whereas K39 ELISA results (IU/ml)
ranged from low to very high (33.19–1990.00; median 596.66)
without a clear correlation to IFA values. In six patients, an
L. infantum-infectionwas determined by PCR, in three patients
there was no appropriate sample available for PCR (Fig. 1).
The four immunosuppressed patients with clinical signs of
disseminated and visceral leishmaniasis showed varying IFA
and K39 ELISA values (Table 3). From all patients, at least
one clinical sample with a positive PCR result was available in
which Leishmania-DNA was detected and specified. Three
Table 1 Primer and













trop TQP tttgtggagttcttgactggc HEX BHQ-1
do/inf TQP tttgtggagttcctgactggc Cy5 BBQ-650
maj TQP tttgtggaattcctgacaggcg FAM BHQ-1
braz TQP aattctgctccaccggcgctga ROX BBQ-650
mIFNg-FW tcaagtggcatagatctggaagaa
mIFNg-RV tggctctgcaggattttcatg
mIFNg-TQP tcaccatccttttgccagttcctccag DY-681 BBQ-650
Table 2 Characteristics of 15 patients with visceral leishmaniasis
Patients K39 ELISA result qualitative
Positive Negative
Travel history or origin 9 1




















Leishmania species 9 1




a No adequate clinical sample available for PCR
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patients were infected with L. infantum. One individual with a
positive bone marrow and blood sample (L. infantum) after a
history of extended steroid application (Tables 3 and 4)
remained negative by K39 ELISA. Of special interest is the
HIV co-infected individual with disseminated L. major-infec-
tion, in whom the highest IFA titers in combination with low
ELISA values were seen. The highest ELISA values occurred
in a patient infected with L. infantumwho showed severe skin
manifestations and clinical signs for VL but very low parasite
concentration in the bone marrow (PCR weakly positive, mi-
croscopy negative).
Follow-up after treatment: Five patients were regularly
followed up after different treatment regiments from 13
(minimum) up to 145 (maximum) weeks. After clinically suc-
cessful therapy, a decline of K39 antibodies was detectable in
all individuals but it followed an individual pattern (Table 4).
The first negative result was recorded for patient L (HIV+) at
51 weeks after the third treatment schedule with glucantime.
Patient M (HIV+) was ELISA negative at 90 weeks after
treatment with pentamidine, whereas patient B was negative
only 122 weeks after treatment with liposomal amphotericin
B. The remaining individuals, children at the age of 17months
(J) and 15 years (F), respectively, had not returned to ELISA
negativity at their final test at 13 or 75 weeks after treatment
with liposomal amphotericin B. Nevertheless, significant
drops in the K39 antibody levels were observed in both
patients.
From two male patients with a history of VL, first serum
samples were tested 8 and 2 years, respectively, after the onset
of treatment. At that time they were clinically asymptomatic
and showed similar IFA values (1:640, 1:320) but a negative
or a moderate K39 ELISA result. At the end of a subsequent
screening at regular intervals for another 4 years, the first
individual (HIV+, PCR−) remained ELISA negative (IFA
1:320), the second individual ELISA moderately positive
(IFA 1:80).
Cutaneous leishmaniasis: When studying the 39 sera from
26 patients with CL (one patient was asymptomatic after spon-
taneous healing of a very small skin lesion) the majority of
sera tested negative by ELISA. IFA values ranged from 1:10
(borderline) to 1:320. Infection was acquired mainly in the
Mediterranean area (L. infantum) and Syria (L. tropica). A
low number of lesions (1–3) existed in 86 % of the patients
for whom clinical reports were available (Table 5). As the
exact size of the lesions was not recorded for most of these
patients, this specific parameter was not included.
Only six patients (23 %) were found ELISA positive or
borderline in their first sample (Table 6). Antibody levels
ranged from low to medium (10.85–524.77 U/ml; median
19.77 U/ml). Four individuals were infected with L. tropica,
two individuals with L. infantum. None of the patients had
clinical symptoms for visceral infection. The highest antibody
concentrations were seen in L. infantum-infected patients with
single or multiple lesions, respectively.
Follow-up after treatment: Follow-up samples were avail-
able from five (initially ELISA-negative) patients (period of
follow-up minimum 13 weeks, maximum 139 weeks). In one
patient, a rise of anti-K39 antibodies was documented
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Fig. 1 K39 ELISA and IFA antibody concentration in nine
immunocompetent patients with visceral leishmaniasis before treatment.
Grey columns: infection with L. infantum; white columns: Leishmania
species not determined
Table 3 Leishmania antibodies and real-time PCR results in immunosuppressed patients with clinical signs of visceral (VL) or disseminated
leishmaniasis (DL)
Patient No. (manifestation) Underlying disease Result real-time PCR Result serology
Sample Species IFA titer K39 ELISA U/ml




20,000 (+) 16.02 (+)
2 (VL) HIV+ Blood+ L.infantum 320 (+) 56.77 (+)




640 (+) 1977.72 (+)




160 (+) 1.82 (−)
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miltefosin, (3) ketoconazole) when the most persistent of the
initially three facial lesions started to regress in size. Low level
antibodies remained detectable for a period of 44 weeks until
the lesion was nearly healed (Fig. 2). The increase in antibod-
ies detected by ELISAwas not accompanied by a rise of IFA
antibodies (1:80).
Discussion
Various serological tests have been developed for the detec-
tion of specific antibodies against Leishmania. Generally in
VL patients, serological assays are known to be sensitive for
diagnosis (Chappuis et al. 2007), whereas in cases of CL se-
rology is considered to be of low predictive value due to low
antibody concentration. There is no consensus regarding the
diagnostic use of the available tests in a specific clinical situ-
ation except for the rK39 antigen-based assays. rK39 positiv-
ity is usually related to the presence of a clinically
symptomatic visceral infection (Srividya et al. 2012). The an-
tigen is part of a large kinesin-related protein expressed pre-
dominantly by amastigotes. The antigen is shared bymembers
of the L. donovani complex (L. chagasi, L. donovani,
L. infantum) (Burns et al. 1993). Burns et al. (1993) reported
a high prevalence of antibodies to K39 in VL patients from
different geographically regions, whereas patients with CL or
mucocutaneous leishmaniasis remained negative. Since its
first description, the antigen has been widely applied either
in a strip test or in an ELISA format and is sufficiently vali-
dated for field use in areas endemic for VL (Chappuis et al.
2007; Maia et al. 2012) or for immigrants from endemic areas
with VL (El-Moamly et al. 2012) but there is little experience
on its performance in people from non-endemic areas who got
infected abroad.
In our study we examined the characteristics of a commer-
cially available K39 ELISA (antigen from L. infantum) in
patients with imported VL and CL in comparison to the IFA,
which is known to be of high diagnostic accuracy (Chappuis
Table 4 Antibody response in
five individuals with visceral
leishmaniasis after initiation of
treatment
Patient Leishmania species Weeks posttreatment Result K39 ELISA Result IFA
U/ml Qual. Titer Qual.
B
Leishmania infantum
0 616.58 + 20,000 +
16 66.5 + 5120 +
43 25.69 + 2560 +
66 56.67 + 1280 +
95 15.77 + 640 +
122 7.64 Neg. 320 +
145 7.26 Neg. 320 +
F
Leishmania infantum
0 516.3 + 20,000 +
6 683.8 + 5120 +
12 635.82 + 5120 +
23 419.03 + 2560 +
46 248.02 + 1280 +
75 169.33 + 640 +
M
Leishmania major
0 16.02 + 20,000 +
12 46.56 + 20,000 +
39 47.39 + 2560 +
46 20.41 + 1280 +
84 19.32 + 640 +
90 13.93 Neg. 640 +
J
Leishmania infantum
0 159.41 + 2560 +
5 95.54 + 640 +
13 21.12 + 320 +
L
Leishmania infantum
0a 56.77 + 640 +
23 23.64 + 640 +
39 30.99 + 640 +
51 9.99 Neg. 320 +
a Follow-up after the third treatment schedule
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et al. 2007). An amastigote-based IFA, similar to the one used
in this study, was found to be at least as sensitive as the direct
agglutination test (El Harith et al. 1989).
We could confirm that all immunocompetent patients with
clinical signs of visceral disease and a high IFA antibody
concentration were also positive by ELISA. A good agree-
ment between DAT and rK39 ELISA is known from symp-
tomatic patients with VL but it is poor in subclinically infected
individuals (Srivastava et al. 2013). In our study, there was no
correlation between the quantitative values of both tests which
use antigens derived from the same developmental stage of the
parasite (amastigotes). The quantitative ELISA results, which
varied from very low (33.9 U/ml) to very high (>1990 U/ml)
suggest that the K39 expression or recognition is different in
individual VL patients of German origin who were infected
with L. infantum in the Mediterranean area. A similar obser-
vation is reported for French VL patients also infected with
L. infantum from the Mediterranean area (Abass et al. 2015).
A variable performance of the rK39 dipstick tests in VL
patients from different geographical areas is well known
(Maia et al. 2012; TDR 2010). In contrast, a qualitative
rK39 ELISA applied in a recent study (Abass et al. 2015)
was most sensitive in immunocompetent patients from all en-
demic regions (96–100 %). The highest antibody
Table 5 Characteristics of 25 patients with clinical signs of cutaneous
leishmaniasis (CL) and a positive IFA-result (golden standard)
Patients K39 ELISA K39 ELISA
positive/borderline negative
Travel history or origin



















L. infantum 2 6
L. tropica 4 6
Unknown 1 6
Table 6 Borderline or positive K39 ELISA in patients with cutaneous leishmaniasis
Patient No. Clinical manifestation IFA (titer) K39ELISA (U/ml) Real-time PCR skin
1 1 lesion lower arm Positive Borderline Positive
(80) (10.58) (L. tropica)
2 1 lesion lower lip Positive Borderline Positive
(40) (12.09) (L. tropica)
3 1 lesion upper lip Positive Positive Positive
(40) (24.08) (L. tropica)
4 2 lesions lower arm Positive Positive Positive
(40) (15.27) (L. tropica)
5 1 large lesion, elbow Positive Positive Positive
(160) (51.46) (L. infantum)
6 10 small lesions, face Positive Positive Positive







33 36 66 77 110 139








Fig. 2 Seroconversion after first treatment in a patient with cutaneous
leishmaniasis and three facial lesions before treatment. Broken line =
cutoff
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concentrations, however, were found in patients from India,
compared to patients from Sudan and France.
A reduced sensitivity (81.8 %) of a rK39 ELISA is
reported for French HIV co-infected patients (Abass
et al. 2015), whereas in Italian HIV+ persons the
ELISA was found more sensitive than an IFA based
on promastigotes (Houghton et al. 1998). Data from
our small cohort of immunosuppressed individuals indi-
cate that the K39 ELISA values may remain very low
or even under the cutoff in heavily infected individuals
although IFA antibodies were at high to medium level.
We could not confirm that the K39 ELISA applied in this
study was generally better in detecting high than low level IFA
antibodies in VL patients as mentioned elsewhere (Abass et al.
2015). Whether differences in antibody production to the
kinesin-related antigen are due to the stage of infection or
parasite load could not be evaluated in our study.
Today, the follow-up of rK39 antibodies after treat-
ment is no longer considered as an adequate control
measure for effective therapy (Vallur et al. 2015).
However, a serological follow-up of our patients with
VL after specific treatment revealed a decline of K39
and IFA antibodies in all successfully treated individuals
within the first 12 months as reported elsewhere
(Gidwani et al. 2011), but the antibody decrease follow-
ed an individual pattern. The earliest documented sero-
negativity in an immunocompetent individual was at
122 weeks (>2 years) after onset of treatment. One pa-
tient even remained ELISA positive for more than
6 years without clinical signs for VL. In contrast to
studies performed in endemic areas, where a large pro-
portion of post kala-azar patients remains seropositive
(rK39 ELISA) after cure (Srivastava et al. 2013), some
for more than 15 years (Gidwani et al. 2011), in our
study group a repeated exposure to Leishmania was not
probable. It is remarkable that in one HIV+ individual
antibody levels had dropped under the detectable level
after treatment at times when Leishmania DNA from
peripheral blood was still detectable by PCR. This find-
ing argues against the K39 ELISA as an instrument for
monitoring immunosuppressed individuals after treat-
ment as suggested elsewhere (Houghton et al. 1998).
In contrast to other authors (Cota et al. 2012;
Houghton et al. 1998) we found the IFA format applied
here was an appropriate test to confirm leishmaniasis in
immunocompetent and immunosuppressed individuals
who were infected in the Old World. However, study
results from different groups may be influenced not on-
ly by the strain and the stage of the parasite used for
antigen preparation but also by the characteristics of the
tested populations (Cota et al. 2012).
As expected, the K39 ELISA was less sensitive in
patients with CL than in patients with VL. Only 23 %
of the patients with CL were positive or borderline by
ELISA, which is in concordance with a recent study
were 29 % of US servicemen (n=59) with active CL
had developed antibodies against rK39 detectable in an
ELISA format. The majority of them were infected with
L. major (20) and only two with L. tropica (Hartzell
et al. 2008), whereas patients from our study were in-
fected with L. tropica and L. infantum, respectively. For
the US servicemen, it was concluded that seropositivity
occurs when more and larger lesions exist, whereas in
our study there was a tendency that infection with
L. infantum induces a more pronounced antibody re-
sponse than infection with L. tropica. In both studies,
antibody concentration was moderate and only few in-
dividuals showed elevated ELISA values at levels com-
parative to patients with VL. The K39 ELISA used in
our study was better in detecting high level IFA anti-
bodies in CL patients but those who were negative by
K39 ELISA did not generally have low IFA titers. The
IFA format used in this study proved to be very sensi-
tive for the diagnosis of CL of the Old World and
antibodies persisted up to 24 months after L. tropica-
infection, which is in concordance with persistence up
to 27 months described earlier (Menzel and Bienzle
1978). We could exclude that ELISA positive CL pa-
tients in our study had clinical signs for visceral infec-
tion. Also, seroconversion which occurred in one patient
only at the end of three consecutive treatment trials was
associated with the resolution of clinical symptoms and
not with a progression of the disease.
With a dipstick assay, which in CL is about two third less
sensitive than the ELISA format (Hartzell et al. 2008), anti-
rK39 antibodies were not detected in Turkish children with
small, non-ulcerating lesions due to L. infantum (Svobodová
et al. 2009), whereas 31 % of Indian patients with CL due to
L. donovani reacted positive (Sharma et al. 2009), a difference
which may be explained by the generally higher antibody
level in the Indian population.
Today, it is well known that a positive anti-K39 re-
sponse is not necessarily associated with active visceral
infection. Antibody prevalence in areas endemic for VL
may be up to 34.4 % in the asymptomatic population
(Hantosh and Al Lami 2013).
In conclusion, we could confirm that a high level of K39
antibodies can indicate an active visceral or disseminated in-
fection. In immunocompetent individuals, the K39 assay al-
lows for reliable detection of visceral leishmaniasis and can
support the post-treatment monitoring. However, low level
positivity, may be the result of a subclinical, a previous or a
clinically cured VL or even indicate cutaneous infection and
can persist up to 6 years after adequate VL treatment.
Srivastava et al. (2013) noted that the use of a second test
(DAT) could improve the poor detection rate of the rK39
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ELISA for asymptomatic individuals in areas endemic for VL.
In non-endemic countries the K39 ELISA tested here can give
additional information when it is run in parallel with a highly
sensitive screening test like the IFA.
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